Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Revenue growth of 17% sequentially was driven by a strategic shift toward testing opportunities with higher collection probability, despite flat volume within the target range of 2,500 to 3,000 tests.
Secured the first Laboratory Benefit Manager (LBM) coverage policy from Concert, which validates EsoGuard's clinical evidence and establishes medical necessity for at-risk patients. Management attributes the delay in the Medicare draft Local Coverage Determination (LCD) to a broad bureaucratic backlog at CMS rather than product-specific issues, noting recent signs of the backlog loosening. The VA commercialization strategy is transitioning from clinical engagement to contract securing, with a focus on the new federal fiscal year beginning October 1.
Health system integration is advancing through EHR-automated patient identification, which streamlines the workflow for identifying and testing appropriate candidates within large provider groups. Strategic resource allocation is being refined to focus on 'MVAC' (Medicare, VA, and Contracted) revenue streams to improve the conversion of test volume into recognized cash flow. A sophisticated cost-effectiveness model is expected to be completed this summer, providing the long-term economic justification required for broader commercial payer adoption.
Management remains confident in securing a positive Medicare draft LCD, which would impact 40% to 50% of the addressable patient population and significantly alter revenue recognition methodology. Future commercial scaling will leverage high incremental margins (approximately 90%) to limit the correlation between increased OpEx and cash burn as volume grows. The Concert LBM policy is expected to serve as a precedent for other laboratory benefit managers, with additional client health plans anticipated to adopt the policy in coming months.
Revenue recognition is expected to shift from a 'cash collected' basis to an 'accrual' basis once sufficient predictive data and stable reimbursement policies are established. Current revenue recognition remains primarily on a cash-collection basis due to insufficient predictive data during the transitional reimbursement phase. The company completed a common stock offering yielding $16.8 million in net proceeds to maintain a cash balance of $33.4 million against an $11.6 million quarterly burn rate.
Out-of-network status remains a headwind for collections, as high patient responsibility portions often limit the conversion of 'allowable amounts' into actual revenue. A $1.7 million mark-to-market adjustment on convertible notes was recorded due to common stock price changes, impacting GAAP other income. Management clarified that the VA has not yet contributed meaningfully to test volume as they are currently in the budgeting and contracting phase.
Extract — continue reading at the source.
